📖

MDS 2026 — Rare Movement Disorders

active

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-mds-2026-rare-movement-disor

Related Entities

events-mds-2026-rare-movement-disorders

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

33

Outgoing

35

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Linked Artifacts (66)

mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

mentions🧫Antiviral Therapy Trial for Parkinson's Disease70%

mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D70%

mentions🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

mentions🧫Tau Pathology Initiation Zone Identification70%

mentions🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr70%

mentions🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me70%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera70%

mentions🧫4R-Tau Targeting Therapies for PSP and CBS70%

mentions🧫Prodromal Parkinson's Disease Biomarker Development — E70%

mentions🧫Alpha-Synuclein Seed Amplification Assay Validation70%

mentions🧫Brainstem Circuit Modulation for PSP70%

mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD70%

mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD70%

mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%

mentions🧫PSP and CBS Biomarker Validation Study70%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera70%

mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne70%

mentions🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas70%

mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back70%

mentions🧫Parkinson's Disease Subtype Classification — Precision 70%

mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise70%

mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%

mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#70%

mentions🧫Cytochrome Therapeutics70%

related🧫Alpha-Synuclein Seed Amplification Assay Validation63%

related🧫Parkinson's Disease Subtype Classification — Precision 63%

related🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin63%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr63%

related🧫Antiviral Therapy Trial for Parkinson's Disease63%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin63%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#63%

related🧫Cytochrome Therapeutics63%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson63%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D63%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me63%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise63%

related🧫Brainstem Circuit Modulation for PSP63%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back63%

related🧫Prodromal Parkinson's Disease Biomarker Development — E63%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 63%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper63%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD63%

related🧫Tau Pathology Initiation Zone Identification63%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD63%

related🧫4R-Tau Targeting Therapies for PSP and CBS63%

related🧫PSP and CBS Biomarker Validation Study63%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas63%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag63%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&63%

related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre63%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne63%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#63%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%

related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%

mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

💬 Discussion